<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724841</url>
  </required_header>
  <id_info>
    <org_study_id>GEM303</org_study_id>
    <nct_id>NCT00724841</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma</brief_title>
  <official_title>A Multi-Center, Open-Label, Phase I/II Study of GEM1777 in Combination With Temozolomide Administered Every 4 Weeks to Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gemin X</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of
      GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor
      activity against a variety of cell lines and models from different tumor origins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GMX1777 will be administered as 3-Hour Infusions in Combination with Temozolomide taken
      orally for the treatment of Metastatic Melanoma. GMX1777 infusion will be given on either day
      1, days 1 and 3, or days 1,3, and 5 every 4 weeks. Temozolomide will be administered on 5
      consecutive days every 4 weeks. No investigational or commercial agents or therapies other
      than those described may be administered with the intent to treat the patient's malignancy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated prematurely due to financial contraints.
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the recommended Phase II dose of GMX1777 in combination with temozolomide</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Learn more about the side effects of taking GMX1777 in combination with temozolomide</measure>
    <time_frame>Within the first 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the disease response to treatment with GMX1777 in combination with temozolomide</measure>
    <time_frame>Within the first 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Learn more about how the body processes GMX1777</measure>
    <time_frame>Within the fisrt 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg/m2 GMX1777 with Temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg/m2 GMX1777 with Temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>62 mg/m2 GMX1777 with Temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg/m2 GMX1777 with Temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg/m2 GMX1777 with Temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 mg/m2 GMX1777 with Temozolomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obatoclax Mesylate</intervention_name>
    <description>Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <other_name>GMX1777</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic melanoma

          -  Up to 1 prior chemotherapy regimen allowed; prior immunotherapy allowed

          -  Normal organ and marrow function

          -  Willing to submit to blood sampling for planned PK/PD analyses

          -  Ability of understand and willingness to sign a written informed consent

        Exclusion Criteria:

          -  No other investigational or commercial agents or therapies

          -  Prior exposure to GMX1777, GMX1778 or CHS828

          -  Patients with uncontrolled, intercurrent illness

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Berger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gemin X, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <disposition_first_submitted>August 28, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 13, 2013</disposition_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

